Comparison Amongst Scleral, Corneal and Amniotic Membrane Grafts to Restore Scleral Thinning

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the use of preserved scleral, corneal and amniotic membrane graft for the surgical repair of scleral thinning of different sizes in patients underwent surgery of pterygium with associated beta therapy .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Amniotic Membrane Associated With Conjunctival Autograft Versus Conjunctival Autograft for Recurrent Pterygia

NCT00802620

Recurrent Pterygia

UNKNOWN PHASE1

Intraoperative Mitomycin C, Amniotic Membrane Transplantation and Conjunctival Autograft for Primary Pterygium

NCT02102776

Pterygium

UNKNOWN NA

Safety Study of a Sutureless Amniotic Membran Transplantation to Treat Ocular Surface Disorders (Expanded Access)

NCT02168790

Corneal Ulcers Corneal Melting

COMPLETED EARLY_PHASE1

Combined Amniotic Membrane and Platelet Rich Plasma Clot for Management of Central Corneal Perforation

NCT03500796

Corneal Perforation

COMPLETED NA

Comparison Between Sutureless and Glue Free Versus Sutured Limbal Conjunctival Autograft in Primary Pterygium Surgery

NCT02009072

Pterygium

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Scleral thinning may occur secondary to different ocular surface conditions, especially in rheumatologic diseases and after surgeries as in pterygium. There are different methods to treat this condition, as to use scleral, corneal and more recently amniotic membrane graft.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Scleral Thinning

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amniotic Membrane Transplantation

Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease

Group Type EXPERIMENTAL

Human Amniotic Membrane Transplantation

Intervention Type PROCEDURE

Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Human Amniotic Membrane Transplantation

Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with corneal scleral defects that have persisted for 1 years or longer, regardless of their cause. These patients will have received corneal-scleral or amniotic membrane transplant in order to correct scleral thinning
* Patients with history of pterygium surgery associated with beta therapy followed by scleral thinning

Exclusion Criteria

* Ocular infection
* Acute ocular inflammatory condition
* Previous ocular surgery in the eye study
* Non-controlled systemic disease such as rheumatoid arthritis

Minimum Eligible Age

40 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No